智通财经APP获悉，中国银河证券发布研报称，短期来看，11月以来国家流感监测周报显示全国流感活 动上升，短期建议关注流感行情。中长期来看，医药板块估值经历较长时间调整，近期已呈现显著结构 性修复趋势：1)持续看好医药创新：创新药BD仍将持续，全球主要央行利率降息趋势有望推动估值进 一步提升。2)医药投融资有望复苏：二级市场行情回暖驱动一级市场投融资回升，CXO及上游景气度持 续向好。3)医疗器械触底回升：招投标数据已有好转，以旧换新积压需求逐步释放。 中国银河证券主要观点如下： 抗病毒药物为主要对因治疗手段，预期治疗效果较好。目前主要的抗流感病毒药物有奥司他韦、扎那米 韦、玛巴洛沙韦、帕拉米韦、昂拉地韦等。耐药性来看，多数毒株对抗病毒药物敏感。据叮当快药数 据，11月15日至21日期间，奥司他韦全国销量同比增长237%，玛巴洛沙韦同比增长180%。除常见对因 治疗的抗病毒药物，另有多款中药、退烧药可在病程中使用，以缓解发热、咽喉疼痛、鼻塞、肌肉酸痛 等症状，具体用药需遵照医嘱。接种流感疫苗是预防流感的重要途径。2025年1月至今，流感疫苗批签 发共373批;其中四价流感疫苗批签发230批，同比增长3%;三价流 ...

Core Viewpoint - The pharmaceutical sector has undergone a significant structural recovery trend after a prolonged period of valuation adjustment, with public fund holdings still below historical averages, and the policy environment in 2025 is expected to improve payment conditions, benefiting innovative drugs and medical devices [1] Group 1: Pharmaceutical Innovation - Continued optimism for pharmaceutical innovation: The second half of the year is expected to see ongoing business development (BD) for innovative drugs, with domestic Class B catalog and commercial insurance policies likely to drive further valuation increases [1] Group 2: Investment and Financing in Pharmaceuticals - Pharmaceutical investment and financing are expected to recover: A prosperous secondary market is anticipated to lead to a rebound in primary market financing, with positive trends in CXO and upstream sectors [1] Group 3: Medical Devices - Medical devices are likely to reach a bottom and recover: Tendering data has begun to show signs of improvement, and pent-up demand from replacement needs is gradually being released [1]